Natixis Advisors
CRNX icon

Natixis Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Natixis Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$815K Buy
21,795
+3,337
+18% +$124K ﹤0.01% 1561
2026
Q1 		$670K Sell
18,458
-1,577
-8% -$70.4K ﹤0.01% 1471
2025
Q4 		$933K Sell
20,035
-31,711
-61% -$1.41M ﹤0.01% 1283
2025
Q3 		$2.15M Buy
51,746
+4,631
+10% +$148K ﹤0.01% 1080
2025
Q2 		$1.35M Buy
47,115
+606
+1% +$18.7K ﹤0.01% 1205
2025
Q1 		$1.56M Buy
46,509
+826
+2% +$30.8K ﹤0.01% 1155
2024
Q4 		$2.34M Buy
45,683
+1,337
+3% +$74.8K ﹤0.01% 1048
2024
Q3 		$2.27M Buy
44,346
+11,870
+37% +$612K ﹤0.01% 1056
2024
Q2 		$1.46M Buy
32,476
+5,052
+18% +$233K ﹤0.01% 1147
2024
Q1 		$1.28M Buy
27,424
+1,883
+7% +$73.7K ﹤0.01% 1151
2023
Q4 		$908K Sell
25,541
-89
-0.3% -$2.73K ﹤0.01% 1232
2023
Q3 		$762K Buy
25,630
+5,243
+26% +$108K ﹤0.01% 1241
2023
Q2 		$367K Buy
20,387
+165
+0.8% +$3.29K ﹤0.01% 1400
2023
Q1 		$325K Buy
20,222
+8,458
+72% +$157K ﹤0.01% 1399
2022
Q4 		$215K Sell
11,764
-84
-0.7% -$1.48K ﹤0.01% 1435
2022
Q3 		$233K Sell
11,848
-29
-0.2% -$591 ﹤0.01% 1422
2022
Q2 		$222K Buy
+11,877
New +$237K ﹤0.01% 1439

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis Advisors's CRNX Position: Q2 2026 in Review

Natixis Advisors increased its Crinetics Pharmaceuticals (CRNX) stake by 18% in Q2 2026, buying an estimated $124K and bringing the position to 21,795 shares worth $815K. The position accounts for ﹤0.01% of the portfolio, ranked #1561.

Natixis Advisors first reported a position in CRNX in Q2 2022 and has held it in 17 quarters since. The position peaked at $2.34M in Q4 2024. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Natixis Advisors held 21,795 shares of Crinetics Pharmaceuticals worth $815K as of Q2 2026.
  • Natixis Advisors bought 3,337 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $124K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1561 holding.
  • Natixis Advisors first reported a position in Crinetics Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • Natixis Advisors's Crinetics Pharmaceuticals position peaked at $2.34M in Q4 2024.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.